| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. | 0 | 2.6 | 1 | 0 |
Cancer of Pancreas
[description not available] | 0 | 3.52 | 4 | 0 |
Carcinoma, Ductal, Pancreatic
[description not available] | 0 | 2.6 | 1 | 0 |
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). | 0 | 3.52 | 4 | 0 |
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS. | 0 | 2.6 | 1 | 0 |
Hematologic Malignancies
[description not available] | 0 | 3.64 | 1 | 1 |
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. | 0 | 3.64 | 1 | 1 |
Astrocytoma, Grade IV
[description not available] | 0 | 3.64 | 1 | 1 |
Hepatocellular Carcinoma
[description not available] | 0 | 3.64 | 1 | 1 |
Cancer of Liver
[description not available] | 0 | 3.64 | 1 | 1 |
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. | 0 | 3.64 | 1 | 1 |
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. | 1 | 5.64 | 1 | 1 |
Liver Neoplasms
Tumors or cancer of the LIVER. | 0 | 3.64 | 1 | 1 |
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES. | 0 | 3.64 | 1 | 1 |
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. | 1 | 5.64 | 1 | 1 |
Recrudescence
[description not available] | 0 | 5.43 | 2 | 1 |
Diffuse Large B-Cell Lymphoma
[description not available] | 0 | 6.46 | 4 | 2 |
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. | 1 | 8.46 | 4 | 2 |
Thrombopenia
[description not available] | 0 | 4.55 | 1 | 1 |
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood. | 0 | 4.99 | 2 | 1 |
Thrombocytopenia
A subnormal level of BLOOD PLATELETS. | 0 | 4.55 | 1 | 1 |
Diffuse Mixed Small and Large Cell Lymphoma
[description not available] | 0 | 5.81 | 3 | 2 |
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. | 1 | 7.81 | 3 | 2 |
B-Cell Chronic Lymphocytic Leukemia
[description not available] | 0 | 2.31 | 1 | 0 |
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease. | 1 | 4.31 | 1 | 0 |
Cancer of Esophagus
[description not available] | 0 | 3.7 | 1 | 1 |
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS. | 0 | 3.7 | 1 | 1 |
Adverse Drug Event
[description not available] | 0 | 4.51 | 1 | 1 |
Kahler Disease
[description not available] | 0 | 4.51 | 1 | 1 |
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. | 0 | 4.51 | 1 | 1 |
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals. | 0 | 4.51 | 1 | 1 |
Innate Inflammatory Response
[description not available] | 0 | 2.11 | 1 | 0 |
Benign Neoplasms
[description not available] | 0 | 2.11 | 1 | 0 |
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. | 0 | 2.11 | 1 | 0 |
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 2.11 | 1 | 0 |